- Home
- GMAB vs EQH Comparison
GMAB vs EQH Comparison
Compare GMAB & EQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- EQH
- Stock Information
- Founded
- GMAB 1999
- EQH 1859
- Country
- GMAB Denmark
- EQH United States
- Employees
- GMAB N/A
- EQH N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- EQH Specialty Insurers
- Sector
- GMAB Health Care
- EQH Finance
- Exchange
- GMAB Nasdaq
- EQH Nasdaq
- Market Cap
- GMAB 17.4B
- EQH 16.2B
- IPO Year
- GMAB N/A
- EQH N/A
- Fundamental
- Price
- GMAB $31.32
- EQH $46.67
- Analyst Decision
- GMAB Strong Buy
- EQH Buy
- Analyst Count
- GMAB 6
- EQH 11
- Target Price
- GMAB $40.40
- EQH $64.18
- AVG Volume (30 Days)
- GMAB 1.8M
- EQH 3.3M
- Earning Date
- GMAB 11-06-2025
- EQH 11-04-2025
- Dividend Yield
- GMAB N/A
- EQH 2.37%
- EPS Growth
- GMAB 132.41
- EQH N/A
- EPS
- GMAB 25.10
- EQH N/A
- Revenue
- GMAB $3,845,670,022.00
- EQH $12,224,000,000.00
- Revenue This Year
- GMAB $24.92
- EQH $17.79
- Revenue Next Year
- GMAB $15.97
- EQH $3.00
- P/E Ratio
- GMAB $1.25
- EQH N/A
- Revenue Growth
- GMAB 29.57
- EQH 13.38
- 52 Week Low
- GMAB $17.24
- EQH $41.39
- 52 Week High
- GMAB $33.65
- EQH $56.61
- Technical
- Relative Strength Index (RSI)
- GMAB 63.22
- EQH 52.01
- Support Level
- GMAB $29.98
- EQH $42.23
- Resistance Level
- GMAB $30.82
- EQH $45.29
- Average True Range (ATR)
- GMAB 0.65
- EQH 1.29
- MACD
- GMAB 0.15
- EQH 0.30
- Stochastic Oscillator
- GMAB 94.93
- EQH 99.22
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About EQH Equitable Holdings Inc.
Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.